godfather of surgery

Chapter 1282 The Choice You Want
When the intelligence from Rolf and Huang Jiacai's negotiations reached Europe, the meeting room where a consensus on "joint negotiations" had just been reached was once again embroiled in debate.

"Inclusive benefits? Tiered pricing? A globally unified framework?" The balding German stared wide-eyed, as if he'd heard a fantasy. "Who does he think he is? The World Health Organization? Or God? What gives him the right to set global rules?"

"This is an insult to our business logic!" The French CEO's face flushed red. "Pricing according to GDP per capita? How much will that squeeze our profit margins?"

“What’s even more frightening is that he explicitly rejected the exclusivity agreement.” The Swiss director said gravely. “This means that he wants to put all of us, including BG, on the same starting line and race against him using his rules. The competition between us will become naked and brutal, while he stands on high ground, holding the power of technology as the referee.”

The American CEO, with his sharp gaze behind his wire-rimmed glasses, listened silently to the crowd's angry shouts and complaints, his fingers swiping rapidly across his tablet, repeatedly reading the intelligence reports. Gradually, the anger on his face was replaced by contemplation.

"Quiet!" His voice wasn't loud, but it instantly silenced the noisy conference room.

Everyone looked at him.

"Ladies and gentlemen," he said, taking off his glasses and rubbing his temples. His voice was tired, but his mind was unusually clear. "We have been swayed by our emotions again. Huang Jiacai's actions just prove his ambition and foresight."

He put his glasses back on and looked around at the crowd: "He saw through the true nature of our so-called joint delegation—nothing more than a mob driven by fear, trying to band together for warmth in order to get better terms in the negotiations. He didn't give us that opportunity at all, but instead announced the new rules of the game directly."

"Why would he do that?" some people wondered.

“Because time is on his side,” the US president said coldly. “Professor Yang Ping’s technological lead is obvious. Otherwise, why would Li Gaoyang and BG side with them? Every day we wait, we lose more market credibility and stock price. Huang Jia can use this time to slowly select partners and even support new, more obedient ones. Don’t forget, it’s not just us who are coveting this technology globally.”

He paused, then emphasized, "More importantly, his proposed universal access and tiered pricing stand on the absolute moral and public opinion high ground. Once made public, it will gain favor and support from developing countries, and even ordinary patients and some health insurance payers in Europe and America. If we stubbornly insist on the high-profit model at that time, we will face not only technological backwardness, but also moral condemnation and overwhelming public pressure. That would be the real disaster. This is an open conspiracy."

The room fell silent again, but this time, the anger was cooling and reason was returning.

"So...we have no choice but to accept his framework?" the German asked with difficulty.

“It’s not just a matter of choice, it’s a necessity,” the US president corrected. “Within this framework, securing the most favorable position and terms for us is the only wise choice we have right now. BG has already gone; it has its leverage, and we have ours—the combined advantages, a broader network of mature markets in Europe and America, deeper localized political and business relationships, and leading auxiliary technologies in certain niche areas. We need to show Huang Jiacai that choosing us will allow his inclusive framework to be implemented faster and more smoothly, reducing friction and risks.”

He stood up, once again demonstrating his decisiveness: "Adjust our strategy immediately! Our joint delegation's goal is no longer to secure exclusivity or priority, but to prove to Ruixing that we are the most capable and sincere partner alliance to implement its global inclusive strategy! Gather our respective case studies and social responsibility reports on reducing healthcare costs and promoting drug accessibility, and compile the specific resources and timelines we can provide for expedited approval, health insurance access, and channel expansion. We will use our strength and service to secure our first-mover advantage in this new game!"

"At the same time," a sharp glint flashed in his eyes, "we privately contacted pharmaceutical regulatory agencies, authoritative medical associations, and key opinion leaders in various countries to lay the groundwork for public opinion and technical support for the special nature of K therapy and its humanitarian exemption to enter the fast-track review process."

A new consensus was quickly reached based on a more sober, yet more resigned, realism. The old giants began to clumsily and eagerly learn to dance under the new rules.

……

Southern Metropolis Daily, Ruixing Group Headquarters.

Song Ziming and Tang Shun knocked on the door and came in, carrying new documents.

“President Huang, our preliminary assessment is in.” Song Ziming placed a brief medical assessment summary on the table. “Li Gaoyang’s condition is indeed not suitable for another surgery. The tumor recurrence is in a dangerous location and has extensive infiltration. K therapy is theoretically feasible, but there are uncertainties. The biggest obstacle is the access rules. According to our experimental rules, Li Gaoyang is a U.S. citizen. Our K therapy must obtain clinical trial qualifications in the United States before Li Gaoyang can obtain clinical trial volunteer status.”

Tang Shun added, "Furthermore, our legal and clinical registry departments have comprehensively assessed that even if we operate under the guise of 'humanitarian aid' or 'emergency clinical trials,' the risk of making an exception for Li Gaoyang alone is extremely high. We have learned a lot from the past: legal risks, public opinion risks, and the possibility that our opponents could use this to attack us for lax rules and data fabrication."

Huang Jiacai turned around, his gaze falling on the evaluation summary, his face revealing neither joy nor anger. "What are Professor Yang's thoughts?"

"Professor Yang said that it's medically feasible to try it, but the procedures must be compliant. He doesn't want a single case to affect the compliance and credibility of the global promotion of K therapy," Song Ziming replied.

Huang Jiacai nodded. Professor Yang's actions showed reverence for life, adherence to rules, and consideration for the long term.

"What are the latest developments of the other major players?"

Huang Jiahui, standing nearby, replied, “Their joint delegation has formally sent a letter requesting talks to be held as soon as possible. The tone was extremely humble, but the specific stance was unclear. In addition, we have monitored reports from some medical industry media and analysts in Europe and North America, and the direction has subtly shifted. There are beginning to be discussions about how to make breakthrough therapies more accessible and how to balance corporate social responsibility with the returns on innovation, which is vaguely laying the groundwork for a new framework that we may propose. There must be someone guiding things behind the scenes.”

Huang Jiacai smiled and said, "It seems that some people have accepted reality and started taking action faster than we thought. That's a good thing."

He continued, "Dr. Song, Dr. Tang, what do you think is the biggest challenge of the inclusive framework we proposed?" Tang Shun pondered for a moment and said, "The difficulty of implementation. The healthcare systems in different countries and regions vary greatly, and the payment capacity, regulatory logic, and interest patterns are intricately intertwined. Tiered pricing sounds wonderful, but how do we accurately define the tiers? How do we prevent drugs from flowing from low-priced areas to high-priced areas? How do we deal with the resistance from local traditional interest groups? This requires extremely meticulous design and strong implementation capabilities, which is far from enough by our own efforts alone."

Song Ziming nodded in agreement: "There are also technical safeguards and risk control. K-therapy and X-2 technology are complex to operate and have extremely high requirements for the medical environment and doctor training. Large-scale promotion requires the establishment of a global technical training, quality control and support system, which is another huge project."

“You’re absolutely right,” Huang Jiacai said calmly. “So what we need is not one or two partners, but a network of ecosystem co-builders. These traditional giants have their deep local roots and political and business resources, and in some emerging markets, we also need to find dynamic and ambitious local companies.”

He tapped the table lightly with his finger: “Our role should be that of a platform builder, a technology standard setter, and a core resource provider. We provide technology and some key products, establish fair access and profit-sharing rules, and attract all parties to leverage their strengths on this platform to jointly expand the market and bring technology to patients. In this process, Ruixing and Sanbo will obtain reasonable R&D returns, technological influence, and most importantly, build our own vast and efficient network that is deeply integrated into the global healthcare system.”

Song Ziming and Tang Shun exchanged a glance, both seeing the shock in each other's eyes. Huang Jiacai's ambition was far greater than they had imagined. This wasn't just about selling technology licenses; it was about spearheading a gradual restructuring of the global healthcare supply chain and payment system.

“Li Gaoyang and BG are role models.” Huang Jiacai’s gaze was profound. “We need a giant like BG to be the first to jump in and accept our rules, even if they are initially unwilling. Its demonstration effect is huge, so this is a rare opportunity. Now is our best time, and we will never have such an opportunity again.”

He paused for a moment, then slowly said, “The rules cannot be broken, but the path can be found. Professor Yang said that it is possible to try in medicine. So, what if BG could use all its resources to promote the expanded compassionate use of K therapy for specific advanced cases or accelerate the approval of clinical trials in the United States? What if they could persuade the FDA to open a fast track based on the highly representative case of Rikoyan?”

Song Ziming's eyes lit up: "In this way, it's not that we're making an exception, but that they've found a path within their own country's rules and framework. We're just responding to applications that meet the requirements, and we've taken the first step steadily towards the world."

“That’s right.” Huang Jiacai nodded. “We need to convey this message to Johannesson and Rolf through appropriate channels. Let them work on it themselves. At the same time, tell Professor Yang’s team to be technically prepared. Once the pathway is opened, we must ensure that the treatment process is foolproof. The most powerful publicity for our technology is that Rigoyang is alive and has good results. Moreover, if Rigoyang is to live, he must stand up and promote our technology.”

Tang Shun exclaimed, "President Huang, you've killed multiple birds with one stone!"

Huang Jiacai’s voice was calm yet powerful: “Rigoyan himself gave us an opportunity, and we must seize it and strive to shape it into what they fear. Healthcare should not just be a business, but a welfare program. But doing good also requires wisdom and means.”

"But...wouldn't it seem immoral of us to do that?" Huang Jiahui asked from the side.

Huang Jiacai laughed and said, "Morality? It's civilized to talk about morality with people, but it's foolish to talk about morality with animals. That's right, we should be civilized people, but we should also be smart people. Smart people should first be able to distinguish between people and animals."

Tang Shun was shocked by Huang Jiacai's words. This guy with only a high school education actually had such insights. He had never studied abroad, but Tang Shun felt that he knew better than him how to deal with people like Li Gaoyang. He could always find the other party's weakness in every confrontation.

……

At almost the same time, in a suite at a high-end hotel in Nandu.

Rolf concluded an emergency video conference with Rikoyan and the BG board. The meeting was filled with heated debate and heavy breathing, but ultimately, Rikoyan's weak yet resolute voice prevailed:
"Accept it. We have no choice... no, this is the only wise choice. Talk within Huang Jiacai's framework and strive for the best cooperation terms. This is for the future of BG. This is a completely new field of healthcare, and we must be among the first to get a standing ticket. Otherwise, in ten or twenty years, we will be eliminated. Throughout business history, countless companies have been eliminated because they could not keep up with technological progress."

At this moment, Rolf leaned wearily against the sofa, his eyes closed. His staff quietly processed documents beside him, preparing materials for the next round of negotiations. They knew that tomorrow's negotiations would be completely different. They were no longer the high-and-mighty demanders, but bidders who needed to prove their worth.

Rolf's phone vibrated with an encrypted message from an unknown number. He opened it; it contained only a short sentence: "Seek a path within the rules, FDA extended use, or accelerated testing."

The sender was unsigned, but Rolf understood instantly. This was a ladder, and also a test—a test of BG's resources and determination in the United States.

He suddenly opened his eyes. “Connect all our resources in Washington, all the medical research institutions and patient advocacy groups we fund, with the goal of pushing the FDA to approve an expanded compassionate use agreement for K therapy for specific advanced cancer patients as quickly as possible, with Mr. Rikoyan as the first applicant. Use all legal resources, at all costs.”

“Yes, sir!” The secretary heard it clearly.

"Do we need the intervention of the media and lobbying groups? I'm afraid the power of medical research institutions and patient advocacy groups alone is not enough," the secretary worried.

Rolf nodded: "We must get them fully involved."

“Okay, this requires a huge amount of special funds. I wonder if the board of directors will be able to provide them?” the secretary expressed his concern again.

Rolf thought for a moment and calmly said, "Release this information to the veterans behind BG Group; their opinions are more reliable than those of the board of directors."

Will they get involved in this kind of thing?

"The desire for immortality will lead them to make the choices we want."